

# PROGRAM

---

**MONDAY 4<sup>TH</sup> MAY**

## DRUG DISCOVERY: TARGETS AND APPROACHES

### Registration

10:30am - 4:30pm

Oceanic Ballroom Foyer

### Welcome

11:45am - 12:00pm

Oceanic East

**Official Opening:** The Hon Jillian Skinner MP, Minister for Health  
and Minister for Medical Research

### Plenary Session 1

12:00pm - 1:00pm

Oceanic East

Chair: Murray Norris

Sponsored by



#### Jason Lewis

Molecular Imaging: A Window into Cancer

*abs# 1*

### Lunch

1:00pm - 2:00pm

Oceanic West & Foyer

### Symposium 1: Target identification and drug discovery

2:00pm - 3:30pm

Oceanic East

Chairs: Ian Street and Nicole Verrills

2:00 PM **Chas Bountra**

Working together to catalyse the discovery of pioneer targets for cancer drug discovery: creating a new, more efficient ecosystem

*abs# 2*

2:45 PM **John Silke**

How to improve a good drug - Tales of the unexpected

*abs# 3*

3:15 PM **Andrew Burgess**

Global phosphoproteomic mapping reveals how phosphatases control mitotic exit and maintain genome stability

*abs# 4*

**Afternoon Tea**  
3:30pm - 4:00pm

Oceanic West & Foyer

**Symposium 2: Genetic/epigenetic targets and therapeutics**

4:00pm - 5:30pm

Oceanic East

Chairs: Joshua McCarroll and Tao Liu

Sponsored by



- 4:00 PM **Chris Jones**  
Paediatric glioblastoma: unique targets in unique diseases *abs# 5*
- 4:45 PM **Susan Clark**  
DNA methylation of estrogen regulated enhancers defines endocrine sensitivity in breast cancer *abs# 6*
- 5:15 PM **Nicholas Clemons**  
Reactivating the p53 stress response to treat oesophageal cancer *abs# 7*

**Welcome Reception**

5:30pm - 7:30pm

Oceanic West & Foyer

Sponsored by CBNS

# TUESDAY 5<sup>TH</sup> MAY

## PRECLINICAL MODELS AND DRUG DELIVERY

### Symposium 3: Tumour heterogeneity/preclinical models

9:00am - 10:30am

Oceanic East

Chairs: Richard Lock and Alex Swarbrick

9:00 AM **Michael Hemann**

The tumor microenvironment drives intra-tumoral heterogeneity in chemotherapeutic response *abs# 8*

9:45 AM **Neil Watkins**

A genome-wide, synthetic lethal screen for innate platinum-resistance genes in lung adenocarcinoma.

*abs# 9*

10:15 AM **Matthias Ernst**

Excessive activation of the Src-kinase HCK in the tumor stroma promotes progression of solid tumors *abs# 10*

### Morning Tea

10:30am - 11:00am

Oceanic West & Foyer

### Symposium 4: Drug delivery

11:00am - 12:30pm

Oceanic East

Chairs: Karen McKenzie and Jamie Fletcher

11:00 AM **Preethi Gunaratne**

Mining The Cancer Genome Atlas (TCGA) database to identify genotype matched tumor suppressor microRNAs toward the next generation of cancer drugs

*abs# 11*

11:45 AM **Phoebe Phillips**

Tackling pancreatic cancer using a novel nanotechnology-siRNA therapeutic

*abs# 12*

12:15 PM **Mathew Vadas**

A new cancer therapeutic that targets angiogenic vessels

*abs# 13*

### Lunch

12:30pm - 1:30pm

Oceanic West & Foyer

## Rapid fire poster presentations

1:30pm - 2:15pm

Oceanic East

Moderator: Greg Arndt

### Don Cameron

Investigating acquired resistance to novel Pol I transcription inhibitors for the treatment of haematologic malignancies *abs# 104*

### Alex Cole

TP53 mutation and p53 immunohistochemistry in high grade serous ovarian cancer. *abs# 109*

### Christopher Fife

Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA activation and transendothelial migration *abs# 114*

### Simon Hogg

BET-bromodomain inhibition induces Myc-independent apoptosis via epigenetic regulation of BCL-2 family proteins in aggressive Myc-driven lymphoma. *abs# 119*

### Cara Toscan

Thioimidazole based compounds reverse glucocorticoid resistance in paediatric acute lymphoblastic leukaemia *abs# 153*

### Luke Jones

Bioluminescence imaging enhances analysis of drug response in a patient-derived xenograft model of paediatric acute lymphoblastic leukaemia *abs# 123*

### Jessica Salmon

Mechanistic insights into HDAC-inhibitors: Linking the Type-I Interferon signaling pathway with differentiation therapy in t(8;21) AML *abs# 142*

### Lorey Smith

Functional genomics of BRAF-driven glycolysis in BRAF<sup>V600</sup> melanoma *abs# 148*

### Orazio Vittorio

Targeting copper metabolism in neuroblastoma using Dextran-Catechin *abs# 157*

### Jacqueline Whitehouse

Cell cycle checkpoint inhibition and cyclophosphamide is an effective combination therapy in a mouse model of paediatric medulloblastoma *abs# 160*

**Afternoon Tea/Poster Session**

2:15pm - 4:00pm

Oceanic West & Foyer

**Sponsored by**



**Plenary Session 2**

4:00pm - 5:00pm

Chair: Michelle Haber

Oceanic East

**Sponsored by**



**Stefan Pfister**

Molecular diagnostics in pediatric (neuro-) oncology in the omics era *abs# 14*

**Bus departs from Crowne Plaza Coogee Beach**

6:30pm

**Conference Dinner**

7:00pm - 10:00pm

**Pier One, Sydney Harbour**

**Sponsored by**



**Bus departs from Pier One, Sydney Harbour**

10:30pm

# WEDNESDAY 6<sup>TH</sup> MAY

## PERSONALISED MEDICINE

### Symposium 5: Biological therapies

9:00am - 10:30am

Oceanic East

Chairs: Glenn Marshall and Debbie Marsh

9:00 AM **Sarah-Jane Dawson**

Biomarker-driven cancer therapy

*abs# 15*

9:30 AM **Deborah White**

Rational therapies and Moving Targets

*abs# 16*

10:00 AM **Marc Achen**

Targeting vascular remodelling in cancer

*abs# 17*

### Morning Tea

10:30am - 11:00am

Oceanic West & Foyer

### Symposium 6: Patient care: Ethical and economic issues in personalised medicine

11:00am - 12:30pm

Oceanic East

Chair: Grant McArthur

11:00 AM **Wendy Lipworth**

Patient care: ethical and economic issues in personalised medicine

*abs# 18*

11:20 AM **Brett Doble**

Constraining healthcare expenditures and determining value for genomic medicine in oncology

*abs# 19*

11:40 AM **Tracy O'Brien**

Not available at time of printing

*abs# 20*

12:00 PM **Panel Discussion**

### Lunch

12:30pm - 1:00pm

Oceanic West & Foyer

## **Symposium 7: Personalised medicine in the clinic**

1:00pm - 2:30pm

Oceanic East

Chairs: David Ziegler and Vanessa Tyrrell

1:00 PM **Grant McArthur**

Overcoming resistance to therapies targeting oncogenes  
*abs# 21*

1:45 PM **Jayesh Desai**

Not available at time of printing *abs# 22*

2:15 PM **Michael Friedlander**

Personalised cancer medicine in the clinic *abs# 23*

### **Afternoon Tea**

2:30pm - 3:00pm

Oceanic West & Foyer

### **Plenary Session 3**

3:00pm - 4:00pm

Oceanic East

Chair: Maria Kavallaris

**Anil Sood**

Not available at time of printing *abs# 24*

### **Award presentation and closing remarks**

4:00pm - 4:15pm

Oceanic East

## POSTER LISTING

---

### **Greg Arndt**

Testing high risk childhood cancer patient cells *in vitro* for potential new drug treatments *abs# 101*

### **Nikola Bowden**

Global demethylation Increases XPC expression and overcomes platinum therapy resistance in melanoma *abs# 102*

### **Frances Byrne**

Identification of a novel glucose oxidation agonist that selectively kills cancer cells *abs# 103*

### **Don Cameron**

Investigating acquired resistance to novel Pol I transcription inhibitors for the treatment of haematologic malignancies *abs# 104*

### **Aur lie Cazet**

Novel approaches to targeting the tumour-stroma coalition in triple negative breast cancers *abs# 105*

### **Leanna Cheung**

High-throughput screening identifies new inhibitors of the multidrug transporter MRP4 *abs# 106*

### **Withdrawn**

*abs# 107*

### **Arjanna Chitranjan**

Establishing *in vitro* and *in vivo* models to develop novel therapeutic approaches for Diffuse Intrinsic Pontine Glioma. *abs# 108*

### **Alex Cole**

*TP53* mutation and p53 immunohistochemistry in high grade serous ovarian cancer. *abs# 109*

### **Robyn Cook**

The Bright Alliance - new ways of working *abs# 110*

### **Stephanie Decollogne**

Mitochondrial and mTOR pathway inhibition synergise to block pancreatic adenocarcinoma development *abs# 111*

### **Kristie Dickson**

Epigenetics informing future treatment strategies for high grade serous ovarian cancer – looking to histones, ubiquitin and chromatin relaxation *abs# 112*

### **Eoin Dodson**

A comprehensive and systematic analysis of miRNA function in neuroblastoma *abs# 113*

### **Christopher Fife**

Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA activation and transendothelial migration *abs# 114*



**Claudia Flemming**

A novel anti-cancer agent that sensitizes neuroblastoma cells to chemotherapy and targets cellular metabolism *abs# 115*

**Laura Gamble**

MYCN coordinately regulates the entire polyamine pathway to maintain high polyamine levels in neuroblastoma *abs# 116*

**Jixuan Gao**

Investigating the therapeutic potential of targeting ABCE1 in neuroblastoma *abs# 117*

**Thomas Gonda**

Targeting transcription factors in cancer – a hard road, but more likely to reach the destination? *abs# 118*

**Simon Hogg**

BET-bromodomain inhibition induces Myc-independent apoptosis via epigenetic regulation of BCL-2 family proteins in aggressive Myc-driven lymphoma. *abs# 119*

**Holly Holliday**

Transcriptional regulation of mammary gland lineage commitment by Inhibitor of Differentiation 4 (Id4) *abs# 120*

**Withdrawn***abs# 121***(Duohui) Vincent Jing**

The glucocorticoid receptor coordinately regulates *BIM* and *BCL2* in paediatric acute lymphoblastic leukaemia cells *abs# 122*

**Luke Jones**

Bioluminescence imaging enhances analysis of drug response in a patient-derived xenograft model of paediatric acute lymphoblastic leukaemia *abs# 123*

**MoonSun Jung**

An 18-gene Myc activity signature for neuroblastoma and other Myc-driven cancers *abs# 124*

**Alvin Kamili**

Modelling personalised medicine in high-risk neuroblastoma *abs# 125*

**Felicity Kao**

Discovery of a small molecule TUBB3/ $\beta$ III-tubulin modulator in lung cancer *abs# 126*

**Mawar Karsa**

Assessing an *in vitro* model of cultured patient-derived xenografts for predicting treatment response *in vivo* *abs# 127*

**Melissa Kartawinata**

Involvement of ATM in the recruitment of human telomerase to telomeres *abs# 128*

**Anchit Khanna**

Identification of CIP2A as a prognostic marker and a therapeutic target in glioblastoma *abs# 129*

**Frederic Li**

Disabled negative feedback regulation by SPROUTY2 sustains EGFR, FGFR and c-MET mediated resistance to BRAF inhibitor treatment in melanoma *abs# 130*

**Pei Liu**

The novel long non-coding RNA RP1X induces N-Myc protein stabilization, tumour cell proliferation and survival *abs# 131*

**Anna Mariana**

the acrf drug discovery centre: an early-stage drug discovery service *abs# 132*

**Shiloh Middlemiss**

Novel therapeutics for mixed lineage leukaemia in infants *abs# 133*

**Riazuddin Mohammed**

The renin angiotensin system in endometrial cancer *abs# 134*

**Andrew Moore**

MEK inhibition and models of resistance in acute myeloid leukaemia. *abs# 135*

**Jayne Murray**

CBL0137, a novel NFkB suppressor and p53 activator, is highly effective in two independent pre-clinical mouse models of neuroblastoma *abs# 136*

**Rose-Marie Olsson**

Development and characterisation of Aurora A kinase inhibitor MLN8237 resistant leukaemia cells *abs# 137*

**Jennifer Ong**

Protein-protein docking for the discovery of novel therapeutics that target the interaction between PTP1B and EGFR *abs# 138*

**Amelia Parker**

$\beta$ III-Tubulin supports cell growth and proliferation of glucose-starved Non-small Cell Lung Cancer cells by modulating multiple stress response signalling pathways. *abs# 139*

**Sela Po'uha**

Stathmin regulation of microRNA/mRNA expression in neuroblastoma cells *abs# 140*

**Aparna Rao**

Do patients with advanced cancer want to discuss and pay for unfunded expensive anticancer drugs? *abs# 141*

**Jessica Salmon**

Mechanistic insights into HDAC-inhibitors: Linking the Type-I interferon signaling pathway with differentiation therapy in t(8;21) AML *abs# 142*

**Darren Saunders**

Systematic identification of ubiquitin ligase substrates *abs# 143*

**David Segal**

Identifying novel cancer cell susceptibilities *abs# 144*

**Jaynish Shah**

Harnessing the power of serum microRNAs to predict surgical outcome for women with ovarian cancer *abs# 145*

**Robert Shearer**

UBR5 regulates primary cilia formation via interactions with multiple centriolar proteins *abs# 146*

**Snega Sinnappan**

A role for the free beta subunit of human chorionic gonadotropin in sensitivity of high grade serous cancer cells to platinum-based chemotherapeutics *abs# 147*

**Lorey Smith**

Functional genomics of BRAF-driven glycolysis in BRAF<sup>V600</sup> melanoma *abs# 148*

**Klaartje Somers**

A novel molecule targeting protein translation, rapidly and selectively induces cell death in Mixed Lineage Leukaemia *abs# 149*

**Jirawas Sornkom**

New approach to AML therapy: Inhibition of rDNA transcription by CX-5461 *abs# 150*

**Ian Street**

Discovery of CTx-0391034 a novel potent and selective inhibitor of PRMT5 *abs# 151*

**Selina Sutton**

Identification of a novel compound that synergistically inhibits cell growth with BRAF inhibitor in BRAF wildtype and NRAS mutant melanoma cells *abs# 152*

**Cara Toscan**

thioimidazoline based compounds reverse glucocorticoid resistance in paediatric acute lymphoblastic leukaemia *abs# 153*

**Joanna Tsang**

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma *abs# 154*

**Maria Tsoli**

Targeting mitochondrial function and the PI3K/AKT/mTOR pathway as a novel therapeutic approach in the treatment of Diffuse Intrinsic Pontine Glioma *abs# 155*

**Nicole Verrills**

PP2A - a novel biomarker and therapeutic target for poor outcome breast cancer *abs# 156*

**Orazio Vittorio**

Targeting copper metabolism in neuroblastoma using Dextran-Catechin *abs# 157*

**Carol Wadham**

Molecular profiling to predict drug sensitivity or resistance in relapsed childhood cancer *abs# 158*

**Yu Wang**

The prorenin receptor as a novel therapeutic target for the treatment of endometrial cancer *abs# 159*

**Jacqueline Whitehouse**

Cell cycle checkpoint inhibition and cyclophosphamide is an effective combination therapy in a mouse model of paediatric medulloblastoma *abs# 160*

**Jason Wong**

Increased density of somatic mutations at core promoters is linked to neutral selection and transcriptional activity *abs# 161*

**Chengyuan Xue**

M606, a novel small molecule inhibitor of MYCN oncoprotein *abs# 162*

**Reichelle Yeo**

Effect of combining EGFR-targeted therapy and metabolic inhibitors in the treatment of sarcoma *abs# 163*

**Denise Yu**

New, highly selective MRP1 inhibitors show promising preclinical activity in neuroblastoma *abs# 164*

# DELEGATE INFORMATION

---

## The Organiser's Desk – ASN Events

The Organiser's registration desk is in the main foyer adjacent to the Session Room. Any enquires can be directed to ASN Staff there.

### The conference registration desk hours are:

**Monday:** 10:30am – 7:00pm      **Tuesday:** 8:30am – 5:30pm

**Wednesday:** 8:30am – 4:00pm

## The Venue

- All scientific sessions will be in **Oceanic East**
- All meal breaks will be held in among the trade displaces in **Oceanic West and the Foyer.**
- The poster session will be held in **Oceanic West and the Foyer.**

## SOCIAL PROGRAM

**Welcome Reception:** Monday night in the trade area, this is included in your registration

**Poster Session:** Tuesday afternoon, to be held in Oceanic West and the Foyer.

**Conference Dinner:** Tuesday evening at Pier One, Sydney Harbour. Tickets must be pre-purchased. Please check with ASN staff.

## SPEAKER PREPARATION INSTRUCTIONS

**ALL** talks are to be pre-loaded to the common PC laptop. You should give your talk on a USB to the technician well before the session you are participating in so that it can be loaded and tested. A volunteer technician will attend the laptop during breaks enabling you to load your talk. **Talks CANNOT be loaded during sessions.**

## DISPLAYING YOUR POSTER

Poster viewing will take place in Oceanic West and the Foyer. Posters can be put up on Monday during afternoon tea and must be taken down after morning tea on Wednesday. Please locate your abstract number in the online app. Velcro will be supplied at the poster board.

## CONFERENCE APP

This year, the conference has uploaded all the abstracts to an online app for your convenience. To access the compatible website on your smart phone or tablet – please use this link; <http://lowy-symposium-2015.m.asnevents.com.au/>. For easy access, we recommend that you save a shortcut to the site to your home screen.

# NOTES

---

# NOTES

---